Using a two-step triage model for women with presumed ovarian mass, IL-6 > 3.75 pg/mL was established as the main triage, supplemented by standard testing (CA125 or RMI score) for ovarian cancer in patients greater than CA125 or RMI alone (misclassification rate 4.54–3.03 percent vs. 9.09–10.60). This evidence concerns the gene MUC16 and ovarian cancer.